BioXcel Therapeutics is trading 6.39% up at $0.84 in after-hours, likely reacting to a recent amendment to its credit agreement that eased liquidity covenants and extended a critical financing deadline. - The company previously reported Q2 results that missed EPS and revenue estimates, with EPS at -$0.490 versus -$0.423 estimated, and revenue at $182K versus $403.32K expected. - On August 11, the company secured an amendment reducing its minimum liquidity covenant to $3.0 million and extending the deadline to secure refinancing until August 21, 2026, offering a short-term reprieve from severe financial pressure. - The stock fell 11.00% during the August 18 regular session, reflecting ongoing concerns about the company's ability to continue as a going concern.